{"gene":"SMPD3","run_date":"2026-06-10T07:46:36","timeline":{"discoveries":[{"year":2017,"finding":"Crystal structure of the human nSMase2 catalytic domain resolved at 1.85-Å reveals a DNase-I-type fold with a hydrophobic track leading to the active site blocked by an evolutionarily conserved 'DK switch' motif. The soluble catalytic domain directly interacts with the membrane-associated N-terminal domain (NTD), which serves as both a membrane anchor and an allosteric activator. The juxtamembrane region linking NTD and catalytic domain is necessary and sufficient for activation. Mutation of the conserved Asp residue in the DK switch disrupts catalysis, allosteric activation, stimulation by phosphatidylserine, and inhibition by GW4869.","method":"Crystal structure (1.85 Å), active-site mutagenesis, in vitro enzyme activity assays, reconstitution of allosteric activation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with mutagenesis and in vitro enzyme reconstitution in a single rigorous study","pmids":["28652336"],"is_preprint":false},{"year":2005,"finding":"SMPD3 is the primary neutral sphingomyelinase active in postnatal development; smpd3−/− mice are devoid of neutral sphingomyelinase activity and develop dwarfism and delayed puberty caused by hypothalamus-induced combined pituitary hormone deficiency. SMPD3 is segregated into detergent-resistant subdomains of Golgi membranes of hypothalamic neurosecretory neurons, where its transient activation modifies the lipid bilayer as an essential step in the Golgi secretory pathway.","method":"Knockout mouse generation (smpd3−/− and smpd2−/−smpd3−/− double mutant), biochemical SMase activity assay, subcellular fractionation into detergent-resistant membrane domains","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with defined enzymatic and phenotypic readout, replicated in double-mutant model","pmids":["15764706"],"is_preprint":false},{"year":2005,"finding":"A deletion in the Smpd3 gene (fragilitas ossium mutation) results in complete loss of SMPD3 enzymatic activity and causes a syndrome of osteogenesis and dentinogenesis imperfecta in mice without detectable collagen defect, establishing SMPD3's enzymatic activity as essential for bone and dentin mineralization.","method":"Positional cloning, enzymatic activity assay confirming loss of activity in fro/fro mice","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — positional cloning with enzymatic loss-of-function confirmation and defined skeletal phenotype","pmids":["16025116"],"is_preprint":false},{"year":2016,"finding":"SMPD3 deficiency disrupts homeostasis of the sphingomyelin–ceramide–diacylglycerol cycle in the Golgi SMPD3-SMS1 compartment. Loss of the fusogenic lipid intermediates ceramide and DAG impairs vesicle formation and transport in the Golgi secretory pathway, causing dysproteostasis, unfolded protein response, ER stress, and apoptosis. In chondrocytes this arrests secretion of extracellular matrix proteins causing skeletal malformation; in hypothalamic neurons it retards proteo-hormone secretion.","method":"smpd3−/− mouse and derived primary chondrocytes; lipidomics (SM, Cer, DAG quantification); immunofluorescence; assessment of UPR/ER stress markers","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — unbiased genetic model with multiple orthogonal biochemical and cell-biological readouts","pmids":["27882938"],"is_preprint":false},{"year":2006,"finding":"TNF-α stimulates acute translocation of nSMase2 from a basal location to the plasma membrane of A549 epithelial cells in a time- and dose-dependent manner, and rapidly increases N-SMase activity. This translocation is regulated by p38-alpha MAPK (but not ERK or JNK); p38 MAPK inhibition abrogates the TNF-α-induced increase in endogenous N-SMase activity. Both p38-alpha MAPK and nSMase2 are required for TNF-α-stimulated up-regulation of VCAM-1 and ICAM-1, largely independently of NF-κB.","method":"Fluorescence microscopy (translocation), in vitro N-SMase activity assay, pharmacological p38/ERK/JNK inhibitors, nSMase2 overexpression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (localization + activity assay + downstream adhesion molecule readout) in single lab","pmids":["17085432"],"is_preprint":false},{"year":2008,"finding":"PKC-delta mediates TNF-α- and PMA-stimulated translocation of nSMase2 from the Golgi to the plasma membrane. PKC-delta acts independently of p38 MAPK for translocation, but does not regulate in vitro N-SMase activity, and PKC-delta and nSMase2 do not co-immunoprecipitate, suggesting indirect regulation. PKC-delta is upstream of nSMase2-dependent induction of VCAM-1 and ICAM-1.","method":"Pharmacological PKC inhibitors, siRNA knockdown of PKC isoforms, fluorescence microscopy of nSMase2 translocation, in vitro N-SMase activity assay, co-immunoprecipitation (negative for direct interaction)","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods but single lab; co-IP was negative, indirect regulation inferred","pmids":["18653803"],"is_preprint":false},{"year":2010,"finding":"nSMase2 is a phosphoprotein phosphorylated exclusively at serine residues. Calcineurin (PP2B) binds directly to nSMase2 and acts as an on/off switch for its phosphorylation: under oxidative stress, calcineurin is inhibited/degraded, releasing nSMase2 from dephosphorylation, resulting in elevated phosphorylation and increased enzymatic activity. A mutant lacking the calcineurin-binding site shows constitutively elevated phosphorylation and activity that no longer responds to oxidative stress.","method":"Phospho-protein analysis (serine-specific), co-immunoprecipitation of calcineurin with nSMase2, calcineurin inhibitors/siRNA, active-site binding-site mutant, in vitro N-SMase activity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct co-IP of calcineurin with nSMase2 plus binding-site mutagenesis and functional activity readout in single rigorous study","pmids":["20106976"],"is_preprint":false},{"year":2004,"finding":"Heterologous expression of mouse NSMase2 in primary rat hepatocytes generates a Mg2+-dependent, EDTA-inhibited and Triton-inhibited neutral sphingomyelinase that increases cellular ceramide levels, demonstrating in situ enzymatic activity. FLAG-tagged NSMase2 localizes to the plasma membrane by immunofluorescence. NSMase2 expression potentiates IL-1β-induced JNK phosphorylation via a PP2A-family phosphatase, possibly by modulating phosphorylation of IRAK.","method":"Adenovirus-mediated gene transfer, in vitro SMase activity assay, ceramide measurement, immunofluorescence localization, JNK phosphorylation assay, PP2A family phosphatase involvement","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple methods (enzymatic activity, localization, signaling readout) but single lab","pmids":["15059969"],"is_preprint":false},{"year":2011,"finding":"nSMase2 is the primary TNF-α-responsive N-SMase isoform in MCF-7 cells; TNF-α induces late increases in N-SMase activity through post-transcriptional mechanisms. Overexpression of nSMase2 (but not nSMase1 or nSMase3) significantly increases cellular ceramide and decreases sphingomyelin. siRNA knockdown of nSMase2 (but not nSMase3) inhibits TNF-α-induced N-SMase activity.","method":"siRNA knockdown, overexpression, in vitro N-SMase activity assay, cellular sphingolipid measurement by mass spectrometry","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (KD + OE + lipid measurement) in single lab","pmids":["21303347"],"is_preprint":false},{"year":2013,"finding":"nSMase2 (nSMase2/SMPD3) regulates exosomal microRNA secretion from cancer cells; its activity is required for exosome-mediated transfer of miR-210 to endothelial cells, which suppresses specific target genes to enhance angiogenesis and promote metastasis.","method":"nSMase2 knockdown/overexpression in cancer cells, exosome isolation, miRNA profiling, functional angiogenesis and metastasis assays in tumor models","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic manipulation with defined mechanistic readout (exosome miRNA content + angiogenesis) but single lab","pmids":["23439645"],"is_preprint":false},{"year":2018,"finding":"Reconstitution of SMPD3 expression in mouse tumor cells lacking the endogenous gene enhances TNF-induced reduction of cell viability, and mutations found in human leukemia AML/ALL cases cause defects in SMPD3 protein stability and localization, demonstrating that SMPD3 function (ceramide pathway) contributes to apoptotic responses in hematopoietic tumor cells.","method":"SMPD3 reconstitution in tumor cell lines, cell viability assay with TNF treatment, sequencing of mutants with functional analysis of stability and localization","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reconstitution experiment plus functional localization analysis of disease mutations, single lab","pmids":["18299447"],"is_preprint":false},{"year":2013,"finding":"In rat hippocampal ischemia, nSMase2 (but not aSMase) activity is induced early in astrocytes (not neurons), driving ceramide accumulation and production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Enhanced binding of nSMase2 with RACK1 and EED is observed post-ischemia. nSMase2 activation is mediated by p38 MAPK downstream of A2B adenosine receptor, and is not blocked via the RACK1/EED/TNF-α receptor pathway.","method":"Four-vessel occlusion and OGD ischemia models, immunoprecipitation (nSMase2 with RACK1/EED), SMase activity assay, p38 MAPK inhibition, A2BAR pharmacology, cytokine mRNA quantification","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus enzymatic assay plus pharmacological epistasis in a defined in vivo model, single lab","pmids":["24007266"],"is_preprint":false},{"year":2016,"finding":"Smpd3 expression in both chondrocytes and osteoblasts is required for normal endochondral bone development. Transgenic rescue of Smpd3 in chondrocytes of fro/fro mice corrects cartilage but not bone abnormalities; conditional knockout in Osx-expressing cells (chondrocytes + osteoblasts) recapitulates the full fro/fro skeletal phenotype. PTHrP downregulates Smpd3 expression in chondrogenic cells through transcription factor SOX9.","method":"Cre-loxP conditional knockout (Col2a1-Cre and Osx-Cre), transgenic rescue, quantitative histology and bone analysis, gene expression analysis in ATDC5 cells","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple conditional genetic models with defined tissue-specific phenotypic rescue/recapitulation","pmids":["27325675"],"is_preprint":false},{"year":2009,"finding":"BMP2 stimulation upregulates smpd3 mRNA expression in C2C12 cells and the transcription factor Runx2 directly binds to Runx2-responsive elements (RRE) in the smpd3 promoter (at -562 to -557 and -355 to -350 regions) to activate its transcription.","method":"BMP2 treatment and Runx2 transfection in C2C12 cells, promoter-reporter assay, EMSA (electrophoretic mobility shift assay)","journal":"BMB reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA demonstrating direct Runx2 binding plus promoter-reporter, single lab","pmids":["19250608"],"is_preprint":false},{"year":2016,"finding":"ATRA regulates nSMase2 transcriptionally through retinoic acid receptor-α via modulation of histone acetylation, independent of Sp1/Sp3/Runx2 and without increased promoter activity. HDAC inhibition with TSA induces nSMase2 comparably to ATRA. The histone acetyltransferases CBP and p300 are required for ATRA-induced nSMase2 expression. HDAC4 and/or HDAC5 act as negative transcriptional regulators of nSMase2.","method":"HDAC inhibitors, siRNA knockdown of CBP/p300/HDACs, reporter assays, RT-qPCR, chromatin analysis","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic and pharmacological perturbations of epigenetic regulators with defined transcriptional readout, single lab","pmids":["27013100"],"is_preprint":false},{"year":2018,"finding":"SMPD3 deficiency in neuronal Golgi compartment impairs vesicular protein transport, causing accumulation of APP, Aβ, and phosphorylated Tau, dysproteostasis, UPR, and apoptosis in smpd3−/− mouse neurons, resulting in progressive cognitive decline with AD-like signatures.","method":"smpd3−/− mouse model, immunoblotting for APP/Aβ/pTau, UPR markers, cognitive/behavioral testing, Golgi transport assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic model with multiple defined molecular readouts, single lab","pmids":["29725009"],"is_preprint":false},{"year":2011,"finding":"ER stress inhibits NSMase2 activity and elevates plasma membrane and intracellular cholesterol in endothelial cells. NSMase2 knockdown decreases eNOS phosphorylation and NO production by ~50% and ~40% respectively, while increasing PM cholesterol. NSMase2 overexpression in ER-stressed cells restores cholesterol to near-control levels and recovers NO production to ~68–74% of controls, establishing NSMase2 as a pivotal regulator of cholesterol homeostasis and eNOS activation.","method":"NSMase2 overexpression and knockdown in BAEC, cholesterol measurement (epifluorescence and cholesterol oxidase), eNOS phosphorylation assay, NO production measurement","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal OE/KD with multiple functional readouts, single lab","pmids":["22063270"],"is_preprint":false},{"year":2019,"finding":"ZIKV infection induces both activity and gene expression of nSMase2/SMPD3 in cortical neurons. Silencing of SMPD3 reduces viral burden and exosome-mediated transmission of ZIKV. GW4869 (nSMase2 inhibitor) reduces ZIKV loads in neurons and in exosomes derived from these cells.","method":"SMPD3 siRNA knockdown, pharmacological inhibition (GW4869), exosome isolation, viral load quantification (qPCR), cryo-EM of neuronal exosomes","journal":"Emerging microbes & infections","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological knockdown with defined viral transmission readout, single lab","pmids":["30866785"],"is_preprint":false},{"year":2018,"finding":"Cambinol inhibits nSMase2 enzyme activity in dose-responsive fashion and suppresses extracellular vesicle production, thereby reducing tau seed propagation in vitro. In vivo oral administration of cambinol reduces nSMase2 activity in the brain. Molecular docking analysis suggests cambinol targets the DK-switch in the nSMase2 active site.","method":"In vitro nSMase2 enzyme activity assay, EV production assay, tau propagation assay, oral in vivo dosing with brain activity measurement, molecular docking","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro enzymatic assay plus in vivo brain activity plus docking; molecular docking is computational, but enzymatic and EV data are experimental, single lab","pmids":["29604274"],"is_preprint":false},{"year":2019,"finding":"nSMase2 inhibition with GW4869 decreases transfer of oligomeric α-synuclein between neuron-like cells and reduces accumulation and aggregation of high-molecular-weight α-syn, establishing nSMase2-dependent EV biogenesis as a route for α-syn propagation.","method":"GW4869 pharmacological inhibition, α-syn transfer assay between neuron-like cells, western blot for α-syn aggregates","journal":"Frontiers in molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological inhibition with defined protein transfer readout; no genetic confirmation, single lab","pmids":["31555088"],"is_preprint":false},{"year":2018,"finding":"nSMase2 deficiency or GW4869 pharmacological inhibition reduces atherosclerotic lesion development in Apoe−/− mice. The anti-inflammatory mechanism involves Nrf2 activation in endothelial cells and macrophages: GW4869 fails to protect when Nrf2 is silenced by siRNA in endothelial cells and is ineffective in LPS-stimulated macrophages from Nrf2-KO mice.","method":"Apoe−/−;Smpd3 genetic mouse model, GW4869 pharmacological inhibition, Nrf2 siRNA knockdown in endothelial cells, macrophages from Nrf2-KO mice, inflammatory gene expression (MCP-1, ICAM-1, VCAM-1 mRNA)","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic + pharmacological inhibition with epistasis through Nrf2 KO/KD, single lab","pmids":["29794115"],"is_preprint":false},{"year":2019,"finding":"Postnatal ablation of Smpd3 causes impaired extracellular matrix mineralization and defective chondrocyte apoptosis at fracture sites. BMP-2 positively regulates Smpd3 expression via p38 MAPK in ATDC5 chondrogenic cells, while PTHrP negatively regulates Smpd3 expression, establishing opposing upstream regulators of SMPD3 in chondrocytes.","method":"Inducible conditional Smpd3 knockout (Smpd3flox/flox; Osx-Cre), tibial fracture model, p38 MAPK inhibition, gene expression analysis","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — inducible genetic model with fracture healing phenotype plus pharmacological pathway dissection, single lab","pmids":["30530524"],"is_preprint":false},{"year":2023,"finding":"Human tau expression in PS19 transgenic mice elevates brain ceramide levels and nSMase2 activity. The selective nSMase2 inhibitor PDDC normalizes both, reduces tau immunostaining, hippocampal neuronal layer thinning, glial activation, and lowers pTau-carrying neuronal-derived EVs in plasma. In a direct tau propagation model, PDDC blocks contralateral spread of tau, confirming nSMase2-generated ceramide drives EV-mediated tau propagation.","method":"Transgenic PS19 mouse model, nSMase2 activity assay, ceramide/sphingomyelin measurement, AAV tau-propagation model, immunohistochemistry, plasma EV isolation and pTau quantification, PDDC oral treatment","journal":"Translational neurodegeneration","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo pharmacological inhibition with multiple orthogonal readouts in two mouse models, single lab","pmids":["38049923"],"is_preprint":false},{"year":2017,"finding":"In murine TLR signaling models of SLE, TLR activation induces abnormal expression of SMPD3 and triggers its translocation from the Golgi apparatus. SMPD3 dysfunction in turn enhances TLR-induced inflammatory responses in B cells and macrophages.","method":"Immunofluorescence of SMPD3 Golgi localization and redistribution, gene expression analysis, B cell and macrophage functional assays with TLR stimulation","journal":"Scandinavian journal of immunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, immunofluorescence localization with limited mechanistic follow-up","pmids":["28889482"],"is_preprint":false},{"year":2023,"finding":"DPTIP, a non-competitive inhibitor of nSMase2, blocks the DK-switch mechanism. Mutation of His463 in nSMase2 reduces DPTIP inhibitory activity, identifying His463 as a crucial residue in the allosteric inhibitory cavity. DPTIP shows antiviral activity against WNV (EC50 0.26 µM) and ZIKV (EC50 1.56 µM) through nSMase2 inhibition.","method":"In vitro nSMase2 activity assay with DPTIP, site-directed mutagenesis of H463A, computational docking, antiviral assay in cell culture","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with enzymatic assay and computational validation in single study, single lab","pmids":["36430407"],"is_preprint":false},{"year":2023,"finding":"SMPD3 expression in odontoblasts is regulated by the Shh-Gli1 pathway: Smpd3 knockdown impairs odontoblast differentiation and reduces Dspp/Dmp1 markers, while Smpd3 overexpression enhances dentinogenic differentiation and promotes dentin formation ex vivo in a Shh-dependent manner.","method":"siRNA knockdown and overexpression in mDPCs, bulk RNA sequencing, Shh pathway inhibition, tooth germ culture, mineralization assays","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic manipulation (KD + OE) with pathway validation (Shh inhibition) and ex vivo confirmation, single lab","pmids":["40639673"],"is_preprint":false},{"year":2023,"finding":"SOXE-family transcription factors SOX9 and SOX10 directly regulate SMPD3 expression in migrating neural crest cells via enhancer sequences in the first intron of the SMPD3 locus. ChIP-seq and nascent transcription analysis confirm that SOX10 directly drives expression of an SMPD3 enhancer specific to migratory neural crest cells.","method":"Enhancer-reporter assay, transcription factor knockdown, ChIP-seq, nascent transcription analysis (GRO-seq or equivalent), in vivo chick/Xenopus neural crest models","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq plus functional enhancer-reporter plus TF knockdown in a defined developmental context, single lab","pmids":["38052296"],"is_preprint":false},{"year":2012,"finding":"NSMase2 (fro/fro) deficiency leads to accumulation of sphingomyelin and dramatic reduction of ceramides in fibroblasts, and causes slow growth with G1/G0 arrest that is corrected by smpd3 transfection, indicating NSMase2 generates ceramides required for cell cycle progression. ASMase mRNA, protein and activity are substantially elevated in fro/fro fibroblasts, suggesting compensatory upregulation; ASMase deficiency does not affect NSMase2 activity.","method":"fro/fro and ASMase−/− mutant mouse fibroblasts, sphingolipid measurement, SMase activity assay, cell cycle analysis, smpd3 transfection rescue","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic rescue experiment with cell cycle and lipid readouts, single lab","pmids":["23046545"],"is_preprint":false},{"year":2024,"finding":"Proximity labeling (APEX2) of nSMase2 in Jurkat cells reveals a plasma membrane proximal protein network that undergoes significant dynamic remodeling within the first 5 minutes of TNFα stimulation. The recruitment of most proximal proteins depends on nSMase2 enzymatic activity. Proteins related to vesicle-mediated transport (recycling endosomes, trans-Golgi network, exocytic vesicles) are significantly enriched in the proximitome of enzymatically active nSMase2 upon TNFα stimulation.","method":"APEX2 proximity labeling, streptavidin affinity purification, quantitative mass spectrometry, nSMase2-APEX2 stable cell line","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity proteomics with enzymatic activity dependence confirmed, single lab","pmids":["39044828"],"is_preprint":false},{"year":2025,"finding":"Glucocorticoids stimulate sEV secretion in neuronal cells through nSMase2 and Rab27a. GC-induced sEV release requires mitochondrial reactive oxygen species production and opening of the mitochondrial permeability transition pore (mPTP) upstream of nSMase2 activation, linking mitochondrial damage to ceramide-driven EV biogenesis.","method":"TIRF microscopy with mCh-CD63-pHluorin pH-sensitive sEV marker, Rab27a and nSMase2 knockdown, mPTP inhibitors, ROS measurement","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live imaging of EV release combined with genetic knockdown and pharmacological pathway dissection, single lab","pmids":["42059363"],"is_preprint":false},{"year":2025,"finding":"HIF-1α is identified as a direct transcriptional activator of SMPD3 in hepatocytes during alcohol-associated liver disease: ChIP assay demonstrates HIF-1α binding to the SMPD3 locus, and liver-specific Hif1α knockdown reduces hepatic SMPD3 expression. Silencing SMPD3 alleviates alcohol-induced lipid accumulation in hepatocytes.","method":"ChIP assay (HIF-1α at SMPD3 locus), liver-specific Hif1α knockdown mouse, SMPD3 siRNA in hepatocytes, ceramide measurement","journal":"Journal of agricultural and food chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct transcriptional regulation plus genetic KD with functional lipid readout, single lab","pmids":["40404566"],"is_preprint":false},{"year":2024,"finding":"CRISPR/Cas9-generated heterozygous full-body and conditional Smpd3 knockout mice show no impact of Smpd3 deficiency on EV release in vitro or in vivo, challenging the view that nSMase2 universally drives EV biogenesis and suggesting a cell-type-specific role. Bone marrow-derived macrophages show reduced EV release only upon Alix deletion, not Smpd3 deletion.","method":"CRISPR/Cas9 Smpd3 knockout mice (full-body and conditional), in vitro and in vivo EV quantification, Alix deletion comparison","journal":"Journal of extracellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with rigorous in vitro and in vivo EV measurement; negative result for nSMase2's universal EV role, single lab","pmids":["39525277"],"is_preprint":false}],"current_model":"SMPD3/nSMase2 is a Mg2+-dependent neutral sphingomyelinase localized to the Golgi membrane and plasma membrane that hydrolyzes sphingomyelin to ceramide and phosphocholine; its catalytic domain adopts a DNase-I fold regulated by an allosteric 'DK switch' activated by an interdomain interaction with the membrane-anchored N-terminal domain and by phosphatidylserine; ceramide and DAG produced by SMPD3 in the Golgi are required for vesicle budding and secretory pathway flux in chondrocytes and hypothalamic neurons, and at the plasma membrane ceramide enrichment drives ESCRT-independent exosome/EV biogenesis that mediates intercellular transfer of miRNAs, tau, and α-synuclein; nSMase2 is activated by TNF-α downstream of p38 MAPK and PKC-delta (controlling its Golgi-to-plasma membrane translocation) and is negatively regulated by calcineurin-mediated dephosphorylation; upstream transcriptional regulators include Runx2, SOX9/SOX10, CBP/p300-mediated histone acetylation (via ATRA/RAR-α), and HIF-1α."},"narrative":{"mechanistic_narrative":"SMPD3 (nSMase2) is a Mg2+-dependent, membrane-associated neutral sphingomyelinase that hydrolyzes sphingomyelin to ceramide, and is the principal neutral sphingomyelinase active in postnatal development [PMID:15764706, PMID:15059969]. Its catalytic domain adopts a DNase-I-type fold whose active site is gated by a conserved 'DK switch'; catalysis requires an allosteric interaction with the membrane-anchored N-terminal domain via a juxtamembrane region, and a conserved Asp in the DK switch is essential for activity, allosteric activation, phosphatidylserine stimulation, and GW4869 inhibition [PMID:28652336]. The ceramide and diacylglycerol generated by SMPD3 in the Golgi SMPD3–SMS1 compartment serve as fusogenic intermediates required for secretory vesicle formation; loss of these lipids in smpd3-deficient cells impairs Golgi vesicle transport and drives dysproteostasis, ER stress, and apoptosis, arresting extracellular matrix secretion in chondrocytes and proteo-hormone secretion in hypothalamic neurons [PMID:15764706, PMID:27882938]. This secretory function makes SMPD3 enzymatic activity essential for endochondral bone and dentin mineralization, where its loss causes osteogenesis/dentinogenesis imperfecta-like skeletal disease in mice [PMID:16025116, PMID:27325675]. At the plasma membrane, ceramide enrichment by SMPD3 supports extracellular vesicle/exosome biogenesis that mediates intercellular transfer of cargo including miRNAs, tau, and α-synuclein [PMID:23439645, PMID:31555088, PMID:38049923], although a genetic knockout study found EV release to be cell-type-specific rather than universally SMPD3-dependent [PMID:39525277]. SMPD3 is acutely activated downstream of TNF-α through p38 MAPK and PKC-delta, which control its Golgi-to-plasma-membrane translocation, and is held in check by direct binding of calcineurin, which dephosphorylates and inactivates it [PMID:17085432, PMID:18653803, PMID:20106976]. Transcriptionally, SMPD3 is driven by Runx2, SOX9/SOX10, retinoic-acid-receptor-mediated histone acetylation via CBP/p300, and HIF-1α in tissue-specific contexts [PMID:19250608, PMID:38052296, PMID:27013100, PMID:40404566].","teleology":[{"year":2004,"claim":"Establishing that nSMase2 is a genuine cellular enzyme answered whether the cloned protein generates ceramide in situ and where it acts.","evidence":"Heterologous adenoviral expression in rat hepatocytes with in vitro SMase assay, ceramide measurement, and immunofluorescence","pmids":["15059969"],"confidence":"Medium","gaps":["Localization to plasma membrane only in overexpression context","Mg2+ dependence shown biochemically but native regulation unaddressed"]},{"year":2005,"claim":"Knockout and positional-cloning studies established SMPD3 as the dominant postnatal neutral sphingomyelinase and tied its enzymatic loss to defined developmental phenotypes.","evidence":"smpd3−/− mice and fro/fro mutant with SMase activity assays, subcellular fractionation, and skeletal/endocrine phenotyping","pmids":["15764706","16025116"],"confidence":"High","gaps":["Molecular link between Golgi ceramide and secretory defect not yet mechanistic","Bone mineralization mechanism unresolved at this stage"]},{"year":2006,"claim":"Identifying TNF-α-driven p38 MAPK control of nSMase2 translocation answered how the enzyme is acutely mobilized in inflammatory signaling.","evidence":"Fluorescence microscopy of translocation, in vitro N-SMase activity, and pharmacological p38/ERK/JNK inhibition in A549 cells","pmids":["17085432"],"confidence":"High","gaps":["Direct effector linking p38 to nSMase2 not identified","Translocation target compartment defined only as plasma membrane"]},{"year":2008,"claim":"PKC-delta was placed as a second, p38-independent regulator of nSMase2 translocation, refining the signaling architecture of activation.","evidence":"PKC inhibitors, siRNA of PKC isoforms, translocation microscopy, activity assay, and negative co-IP","pmids":["18653803"],"confidence":"Medium","gaps":["Regulation inferred to be indirect; no direct PKC-delta–nSMase2 interaction","Intermediate effector between PKC-delta and translocation unknown"]},{"year":2010,"claim":"Discovery that calcineurin directly binds and dephosphorylates nSMase2 established a phosphorylation on/off switch coupling oxidative stress to enzyme activity.","evidence":"Serine-phospho analysis, calcineurin co-IP, calcineurin-binding-site mutant, and activity assays","pmids":["20106976"],"confidence":"High","gaps":["Kinase responsible for the activating phosphorylation not identified","Specific phosphoserine sites not mapped"]},{"year":2011,"claim":"Isoform-specificity and cholesterol/eNOS work showed nSMase2 is the chief TNF-responsive N-SMase and a regulator of membrane lipid homeostasis beyond ceramide.","evidence":"siRNA/overexpression of nSMase isoforms with mass-spec lipid measurement; reciprocal OE/KD in endothelial cells with cholesterol and NO readouts","pmids":["21303347","22063270"],"confidence":"Medium","gaps":["Mechanism linking ceramide to cholesterol redistribution unresolved","Post-transcriptional TNF-α induction mechanism undefined"]},{"year":2013,"claim":"Linking nSMase2 to exosomal miRNA secretion and to ischemic astrocyte inflammation extended its role from intracellular trafficking to intercellular signaling.","evidence":"nSMase2 knockdown/overexpression with exosome isolation and miRNA transfer assays; ischemia models with nSMase2–RACK1/EED co-IP and p38/A2BAR pharmacology","pmids":["23439645","24007266"],"confidence":"Medium","gaps":["RACK1/EED interaction functional consequence not resolved","Whether ceramide directly nucleates exosomal cargo loading untested"]},{"year":2016,"claim":"Defining the SMPD3-SMS1 sphingomyelin–ceramide–DAG cycle and tissue-specific genetic dissection established the mechanism by which SMPD3 loss disrupts the secretory pathway and bone development.","evidence":"smpd3−/− mice and chondrocytes with lipidomics and UPR markers; conditional Cre-loxP knockouts and transgenic rescue; ATRA/CBP/p300 transcriptional analysis","pmids":["27882938","27325675","27013100"],"confidence":"High","gaps":["Identity of vesicle-budding machinery sensing ceramide/DAG unknown","How epigenetic regulation integrates with developmental signals unresolved"]},{"year":2017,"claim":"The crystal structure resolved the catalytic mechanism, revealing the DNase-I fold, the DK-switch gate, and allosteric activation by the membrane-anchored NTD.","evidence":"1.85-Å crystal structure with active-site mutagenesis and reconstitution of allosteric activation","pmids":["28652336"],"confidence":"High","gaps":["Full-length membrane-embedded structure not solved","Conformational dynamics of DK-switch in vivo not captured"]},{"year":2018,"claim":"Connecting SMPD3 to tumor apoptotic responses, AML/ALL mutations, and skeletal/dental developmental signaling broadened its disease relevance and identified druggable inhibition of the DK switch.","evidence":"SMPD3 reconstitution and TNF viability assays with disease-mutant stability/localization analysis; cambinol enzyme/EV/tau assays with docking; inducible chondrocyte knockout fracture model","pmids":["18299447","29604274","30530524"],"confidence":"Medium","gaps":["Whether AML/ALL mutations are driver events untested","In vivo selectivity of cambinol for the DK switch not confirmed structurally"]},{"year":2019,"claim":"Pharmacological and genetic inhibition established nSMase2-dependent EV biogenesis as a conserved route for spread of pathogenic proteins and viruses and for vascular inflammation.","evidence":"GW4869 and siRNA studies of α-syn and ZIKV transfer; Apoe−/−;Smpd3 atherosclerosis model with Nrf2 epistasis; AD-like phenotype in smpd3−/− neurons","pmids":["31555088","30866785","29794115","29725009"],"confidence":"Medium","gaps":["α-syn work lacks genetic confirmation","Mechanism linking ceramide EVs to Nrf2 activation undefined"]},{"year":2023,"claim":"In vivo inhibitor work and additional structural/transcriptional studies confirmed ceramide-driven EV-mediated tau propagation and mapped further regulatory inputs to SMPD3.","evidence":"PS19 tauopathy and tau-propagation models with selective nSMase2 inhibitor PDDC; DPTIP/H463A DK-switch mutagenesis with antiviral assays; SOX9/SOX10 ChIP-seq and enhancer analysis; Shh-Gli1 odontoblast study","pmids":["38049923","36430407","38052296","40639673"],"confidence":"Medium","gaps":["Whether plasma EV pTau is a faithful biomarker of brain activity not established","His463 allosteric cavity not structurally resolved with bound inhibitor"]},{"year":2024,"claim":"Proximity proteomics and a rigorous knockout challenged the universality of nSMase2-driven EV release, defining its trafficking proximitome while revealing cell-type-specific dependence.","evidence":"APEX2 proximity labeling in Jurkat cells with TNFα stimulation; CRISPR/Cas9 Smpd3 knockout mice with in vitro/in vivo EV quantification and Alix comparison","pmids":["39044828","39525277"],"confidence":"Medium","gaps":["Direct binding partners within the proximitome not validated","Determinants of cell-type EV dependence unidentified"]},{"year":2025,"claim":"Stress-coupled regulation studies linked mitochondrial damage and HIF-1α transcription to SMPD3 activation in neuronal EV release and hepatic lipid handling.","evidence":"TIRF imaging of glucocorticoid-induced sEV release with nSMase2/Rab27a knockdown and mPTP/ROS dissection; HIF-1α ChIP and liver-specific knockdown with ceramide readout","pmids":["42059363","40404566"],"confidence":"Medium","gaps":["Mechanism coupling mitochondrial ROS/mPTP to nSMase2 activation undefined","Direct vs indirect HIF-1α binding site not mapped at base resolution"]},{"year":null,"claim":"It remains unresolved which cell types and physiological contexts genuinely require SMPD3 for EV biogenesis versus secretory trafficking, and what kinase and effector machinery couple upstream signals to its activation and vesicle budding.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Cell-type determinants of EV dependence unknown","Activating kinase and ceramide-sensing budding machinery unidentified","Full-length membrane-embedded structure and in-cell DK-switch dynamics unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1,7]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,7,8]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[1,3,5,23]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4,5,7]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[3,8,27]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[9,22]},{"term_id":"R-HSA-9609507","term_label":"Protein localization","supporting_discovery_ids":[1,3,15]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[9,28,29]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[12,26]}],"complexes":[],"partners":["SMS1","CALCINEURIN","RACK1","EED"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NY59","full_name":"Sphingomyelin phosphodiesterase 3","aliases":["Neutral sphingomyelinase 2","nSMase-2","nSMase2","Neutral sphingomyelinase II"],"length_aa":655,"mass_kda":71.1,"function":"Catalyzes the hydrolysis of sphingomyelin to form ceramide and phosphocholine. Ceramide mediates numerous cellular functions, such as apoptosis and growth arrest, and is capable of regulating these 2 cellular events independently. Also hydrolyzes sphingosylphosphocholine. Regulates the cell cycle by acting as a growth suppressor in confluent cells. Probably acts as a regulator of postnatal development and participates in bone and dentin mineralization (PubMed:10823942, PubMed:14741383, PubMed:15051724). Binds to anionic phospholipids (APLs) such as phosphatidylserine (PS) and phosphatidic acid (PA) that modulate enzymatic activity and subcellular location. May be involved in IL-1-beta-induced JNK activation in hepatocytes (By similarity). May act as a mediator in transcriptional regulation of NOS2/iNOS via the NF-kappa-B activation under inflammatory conditions (By similarity)","subcellular_location":"Golgi apparatus membrane; Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q9NY59/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SMPD3","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SMPD3","total_profiled":1310},"omim":[{"mim_id":"610457","title":"SPHINGOMYELIN PHOSPHODIESTERASE 4, NEUTRAL MEMBRANE; SMPD4","url":"https://www.omim.org/entry/610457"},{"mim_id":"605777","title":"SPHINGOMYELIN PHOSPHODIESTERASE 3, NEUTRAL MEMBRANE; SMPD3","url":"https://www.omim.org/entry/605777"},{"mim_id":"603498","title":"SPHINGOMYELIN PHOSPHODIESTERASE 2, NEUTRAL MEMBRANE; SMPD2","url":"https://www.omim.org/entry/603498"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Endoplasmic reticulum","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"intestine","ntpm":57.9},{"tissue":"lymphoid tissue","ntpm":48.4}],"url":"https://www.proteinatlas.org/search/SMPD3"},"hgnc":{"alias_symbol":["NSMASE2"],"prev_symbol":[]},"alphafold":{"accession":"Q9NY59","domains":[{"cath_id":"-","chopping":"2-94","consensus_level":"medium","plddt":88.5945,"start":2,"end":94},{"cath_id":"3.60.10.10","chopping":"97-102_112-165_342-654","consensus_level":"high","plddt":90.8449,"start":97,"end":654}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NY59","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NY59-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NY59-F1-predicted_aligned_error_v6.png","plddt_mean":75.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SMPD3","jax_strain_url":"https://www.jax.org/strain/search?query=SMPD3"},"sequence":{"accession":"Q9NY59","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NY59.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NY59/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NY59"}},"corpus_meta":[{"pmid":"23439645","id":"PMC_23439645","title":"Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23439645","citation_count":630,"is_preprint":false},{"pmid":"29141446","id":"PMC_29141446","title":"Myocardial reparative functions of exosomes from mesenchymal stem cells are enhanced by hypoxia treatment of the cells via transferring microRNA-210 in an nSMase2-dependent way.","date":"2017","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/29141446","citation_count":238,"is_preprint":false},{"pmid":"15764706","id":"PMC_15764706","title":"Neutral sphingomyelinase 2 (smpd3) in the control of postnatal growth and development.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15764706","citation_count":140,"is_preprint":false},{"pmid":"16025116","id":"PMC_16025116","title":"A deletion in the gene encoding sphingomyelin phosphodiesterase 3 (Smpd3) results in osteogenesis and dentinogenesis imperfecta in the mouse.","date":"2005","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16025116","citation_count":137,"is_preprint":false},{"pmid":"30866785","id":"PMC_30866785","title":"Exosomes mediate Zika virus transmission through SMPD3 neutral Sphingomyelinase in cortical neurons.","date":"2019","source":"Emerging microbes & infections","url":"https://pubmed.ncbi.nlm.nih.gov/30866785","citation_count":108,"is_preprint":false},{"pmid":"29794115","id":"PMC_29794115","title":"nSMase2 (Type 2-Neutral Sphingomyelinase) Deficiency or Inhibition by GW4869 Reduces Inflammation and Atherosclerosis in Apoe-/- Mice.","date":"2018","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29794115","citation_count":94,"is_preprint":false},{"pmid":"17085432","id":"PMC_17085432","title":"Role for neutral sphingomyelinase-2 in tumor necrosis factor alpha-stimulated expression of vascular cell adhesion molecule-1 (VCAM) and intercellular adhesion molecule-1 (ICAM) in lung epithelial cells: p38 MAPK is an upstream regulator of nSMase2.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17085432","citation_count":94,"is_preprint":false},{"pmid":"28652336","id":"PMC_28652336","title":"Structure of human nSMase2 reveals an interdomain allosteric activation mechanism for ceramide generation.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28652336","citation_count":91,"is_preprint":false},{"pmid":"15059969","id":"PMC_15059969","title":"Expression of neutral sphingomyelinase-2 (NSMase-2) in primary rat hepatocytes modulates IL-beta-induced JNK activation.","date":"2004","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/15059969","citation_count":75,"is_preprint":false},{"pmid":"18299447","id":"PMC_18299447","title":"Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18299447","citation_count":71,"is_preprint":false},{"pmid":"24007266","id":"PMC_24007266","title":"Early activation of nSMase2/ceramide pathway in astrocytes is involved in ischemia-associated neuronal damage via inflammation in rat hippocampi.","date":"2013","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24007266","citation_count":68,"is_preprint":false},{"pmid":"16938269","id":"PMC_16938269","title":"Neutral sphingomyelinases and nSMase2: bridging the gaps.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16938269","citation_count":65,"is_preprint":false},{"pmid":"18653803","id":"PMC_18653803","title":"Regulation of neutral sphingomyelinase-2 (nSMase2) by tumor necrosis factor-alpha involves protein kinase C-delta in lung epithelial cells.","date":"2008","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18653803","citation_count":64,"is_preprint":false},{"pmid":"20106976","id":"PMC_20106976","title":"Neutral sphingomyelinase 2 (nSMase2) is a phosphoprotein regulated by calcineurin (PP2B).","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20106976","citation_count":56,"is_preprint":false},{"pmid":"33798648","id":"PMC_33798648","title":"Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases.","date":"2021","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/33798648","citation_count":52,"is_preprint":false},{"pmid":"27806113","id":"PMC_27806113","title":"Inhibiting Extracellular Vesicle Release from Human Cardiosphere Derived Cells with Lentiviral Knockdown of nSMase2 Differentially Effects Proliferation and Apoptosis in Cardiomyocytes, Fibroblasts and Endothelial Cells In Vitro.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27806113","citation_count":48,"is_preprint":false},{"pmid":"21303347","id":"PMC_21303347","title":"Neutral sphingomyelinase 2 (nSMase2) is the primary neutral sphingomyelinase isoform activated by tumour necrosis factor-α in MCF-7 cells.","date":"2011","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/21303347","citation_count":47,"is_preprint":false},{"pmid":"31555088","id":"PMC_31555088","title":"Inhibition of nSMase2 Reduces the Transfer of Oligomeric α-Synuclein Irrespective of Hypoxia.","date":"2019","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31555088","citation_count":41,"is_preprint":false},{"pmid":"27882938","id":"PMC_27882938","title":"Neutral sphingomyelinase (SMPD3) deficiency disrupts the Golgi secretory pathway and causes growth inhibition.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/27882938","citation_count":37,"is_preprint":false},{"pmid":"38582300","id":"PMC_38582300","title":"Sedanolide alleviates DSS-induced colitis by modulating the intestinal FXR-SMPD3 pathway in mice.","date":"2024","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/38582300","citation_count":33,"is_preprint":false},{"pmid":"27325675","id":"PMC_27325675","title":"Smpd3 Expression in both Chondrocytes and Osteoblasts Is Required for Normal Endochondral Bone Development.","date":"2016","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27325675","citation_count":30,"is_preprint":false},{"pmid":"33875010","id":"PMC_33875010","title":"Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson's disease model.","date":"2021","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/33875010","citation_count":28,"is_preprint":false},{"pmid":"29604274","id":"PMC_29604274","title":"Suppression of tau propagation using an inhibitor that targets the DK-switch of nSMase2.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29604274","citation_count":28,"is_preprint":false},{"pmid":"26722292","id":"PMC_26722292","title":"Abnormal methylation status of FBXW10 and SMPD3, and associations with clinical characteristics in clear cell renal cell carcinoma.","date":"2015","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26722292","citation_count":25,"is_preprint":false},{"pmid":"29725009","id":"PMC_29725009","title":"SMPD3 deficiency perturbs neuronal proteostasis and causes progressive cognitive impairment.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/29725009","citation_count":23,"is_preprint":false},{"pmid":"19250608","id":"PMC_19250608","title":"Upregulation of smpd3 via BMP2 stimulation and Runx2.","date":"2009","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/19250608","citation_count":23,"is_preprint":false},{"pmid":"38049923","id":"PMC_38049923","title":"Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer's disease mouse model.","date":"2023","source":"Translational neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/38049923","citation_count":21,"is_preprint":false},{"pmid":"35984620","id":"PMC_35984620","title":"α2,6-Sialylation promotes hepatocellular carcinoma cells migration and invasion via enhancement of nSmase2-mediated exosomal miRNA sorting.","date":"2022","source":"Journal of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35984620","citation_count":19,"is_preprint":false},{"pmid":"30530524","id":"PMC_30530524","title":"Role of SMPD3 during Bone Fracture Healing and Regulation of Its Expression.","date":"2019","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30530524","citation_count":18,"is_preprint":false},{"pmid":"22063270","id":"PMC_22063270","title":"Endoplasmic reticulum stress-mediated inhibition of NSMase2 elevates plasma membrane cholesterol and attenuates NO production in endothelial cells.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22063270","citation_count":18,"is_preprint":false},{"pmid":"28889482","id":"PMC_28889482","title":"TLR-Induced SMPD3 Defects Enhance Inflammatory Response of B Cell and Macrophage in the Pathogenesis of SLE.","date":"2017","source":"Scandinavian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28889482","citation_count":18,"is_preprint":false},{"pmid":"33208172","id":"PMC_33208172","title":"The nSMase2/Smpd3 gene modulates the severity of muscular dystrophy and the emotional stress response in mdx mice.","date":"2020","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33208172","citation_count":17,"is_preprint":false},{"pmid":"28961856","id":"PMC_28961856","title":"Involvement of Cryptosporidium parvum Cdg7_FLc_1000 RNA in the Attenuation of Intestinal Epithelial Cell Migration via Trans-Suppression of Host Cell SMPD3.","date":"2017","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/28961856","citation_count":17,"is_preprint":false},{"pmid":"36297501","id":"PMC_36297501","title":"Dendrimer-Conjugated nSMase2 Inhibitor Reduces Tau Propagation in Mice.","date":"2022","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/36297501","citation_count":16,"is_preprint":false},{"pmid":"25047167","id":"PMC_25047167","title":"Effect of procysteine on aging-associated changes in hepatic GSH and SMase: evidence for transcriptional regulation of smpd3.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/25047167","citation_count":16,"is_preprint":false},{"pmid":"39616150","id":"PMC_39616150","title":"A blood glucose fluctuation-responsive delivery system promotes bone regeneration and the repair function of Smpd3-reprogrammed BMSC-derived exosomes.","date":"2024","source":"International journal of oral science","url":"https://pubmed.ncbi.nlm.nih.gov/39616150","citation_count":15,"is_preprint":false},{"pmid":"27013100","id":"PMC_27013100","title":"ATRA transcriptionally induces nSMase2 through CBP/p300-mediated histone acetylation.","date":"2016","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/27013100","citation_count":15,"is_preprint":false},{"pmid":"36894641","id":"PMC_36894641","title":"Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR-/- mice.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36894641","citation_count":14,"is_preprint":false},{"pmid":"27444010","id":"PMC_27444010","title":"The Expression of PHOSPHO1, nSMase2 and TNAP is Coordinately Regulated by Continuous PTH Exposure in Mineralising Osteoblast Cultures.","date":"2016","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/27444010","citation_count":12,"is_preprint":false},{"pmid":"31199918","id":"PMC_31199918","title":"Neutral Sphingomyelinase 2 (SMPD3) Deficiency in Mice Causes Chondrodysplasia with Unimpaired Skeletal Mineralization.","date":"2019","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31199918","citation_count":12,"is_preprint":false},{"pmid":"26548718","id":"PMC_26548718","title":"The hyaluronic acid inhibitor 4-methylumbelliferone is an NSMase2 activator-role of Ceramide in MU anti-tumor activity.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26548718","citation_count":11,"is_preprint":false},{"pmid":"36430407","id":"PMC_36430407","title":"Allosteric Inhibition of Neutral Sphingomyelinase 2 (nSMase2) by DPTIP: From Antiflaviviral Activity to Deciphering Its Binding Site through In Silico Studies and Experimental Validation.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36430407","citation_count":9,"is_preprint":false},{"pmid":"39044828","id":"PMC_39044828","title":"Dynamic changes in the proximitome of neutral sphingomyelinase-2 (nSMase2) in TNFα stimulated Jurkat cells.","date":"2024","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39044828","citation_count":8,"is_preprint":false},{"pmid":"37765332","id":"PMC_37765332","title":"Microglial-Targeted nSMase2 Inhibitor Fails to Reduce Tau Propagation in PS19 Mice.","date":"2023","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/37765332","citation_count":8,"is_preprint":false},{"pmid":"35163475","id":"PMC_35163475","title":"Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via nSMase2/Smpd3, Satellite, and Immune Cells in Duchenne Muscular Dystrophy.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163475","citation_count":7,"is_preprint":false},{"pmid":"39895262","id":"PMC_39895262","title":"Genistein alleviates rheumatoid arthritis by inhibiting fibroblast-like synovial exosome secretion regulated by the Rab27/nSMase2/Mfge8 pathway.","date":"2025","source":"Food & function","url":"https://pubmed.ncbi.nlm.nih.gov/39895262","citation_count":7,"is_preprint":false},{"pmid":"25555205","id":"PMC_25555205","title":"Hyaluronan synthase-2 upregulation protects smpd3-deficient fibroblasts against cell death induced by nutrient deprivation, but not against apoptosis evoked by oxidized LDL.","date":"2014","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/25555205","citation_count":7,"is_preprint":false},{"pmid":"24585429","id":"PMC_24585429","title":"Inducible transient expression of Smpd3 prevents early lethality in fro/fro mice.","date":"2014","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/24585429","citation_count":4,"is_preprint":false},{"pmid":"39812915","id":"PMC_39812915","title":"Role of Acorus calamus extract in reducing exosome secretion by targeting Rab27a and nSMase2: a therapeutic approach for breast cancer.","date":"2025","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/39812915","citation_count":4,"is_preprint":false},{"pmid":"40404566","id":"PMC_40404566","title":"SMPD3 Inhibition Contributes to Nicotinamide-Ameliorated Hepatic Steatosis in Chronic Alcohol-Fed Mice.","date":"2025","source":"Journal of agricultural and food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40404566","citation_count":3,"is_preprint":false},{"pmid":"39525277","id":"PMC_39525277","title":"Challenging the conventional wisdom: Re-evaluating Smpd3's role in extracellular vesicle biogenesis.","date":"2024","source":"Journal of extracellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/39525277","citation_count":3,"is_preprint":false},{"pmid":"40226357","id":"PMC_40226357","title":"SMPD3 as a Potential Biomarker and Therapeutic Target in Hepatocellular Carcinoma.","date":"2025","source":"International journal of genomics","url":"https://pubmed.ncbi.nlm.nih.gov/40226357","citation_count":3,"is_preprint":false},{"pmid":"23046545","id":"PMC_23046545","title":"Evidence for coordination of lysosomal (ASMase) and plasma membrane (NSMase2) forms of sphingomyelinase from mutant mice.","date":"2012","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/23046545","citation_count":3,"is_preprint":false},{"pmid":"39171374","id":"PMC_39171374","title":"Transcriptomics analysis reveals potential regulatory role of nSMase2 (Smpd3) in nervous system development and function of middle-aged mouse brains.","date":"2024","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/39171374","citation_count":2,"is_preprint":false},{"pmid":"39677286","id":"PMC_39677286","title":"Exploring the Role of SMPD3 in the lncRNA-miRNA-mRNA Regulatory Network in TBI Progression by Influencing Energy Metabolism.","date":"2024","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/39677286","citation_count":2,"is_preprint":false},{"pmid":"39399775","id":"PMC_39399775","title":"nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/39399775","citation_count":1,"is_preprint":false},{"pmid":"38052296","id":"PMC_38052296","title":"SMPD3 expression is spatially regulated in the developing embryo by SOXE factors.","date":"2023","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/38052296","citation_count":1,"is_preprint":false},{"pmid":"40639673","id":"PMC_40639673","title":"Smpd3 regulates odontoblast differentiation through the Shh-Gli1 pathway.","date":"2025","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/40639673","citation_count":1,"is_preprint":false},{"pmid":"37502930","id":"PMC_37502930","title":"Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in murine Alzheimer's disease.","date":"2023","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/37502930","citation_count":1,"is_preprint":false},{"pmid":"41279432","id":"PMC_41279432","title":"Glucocorticoids regulate small extracellular vesicle (sEV) release via activation of nSMase2.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41279432","citation_count":1,"is_preprint":false},{"pmid":"39861669","id":"PMC_39861669","title":"Pharmacokinetic Evaluation of Neutral Sphinghomyelinase2 (nSMase2) Inhibitor Prodrugs in Mice and Dogs.","date":"2024","source":"Pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/39861669","citation_count":0,"is_preprint":false},{"pmid":"42059363","id":"PMC_42059363","title":"Glucocorticoids regulate small extracellular vesicle release via activation of nSMase2.","date":"2026","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/42059363","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.04.686473","title":"Lipid Droplets mediated Japanese Encephalitis Virus small Extracellular Vesicle Release","date":"2025-11-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.04.686473","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.31.665751","title":"Secretion and transfer of adipose lipoprotein lipase utilizes neutral sphingomyelinase 2 generated exosomes","date":"2025-08-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.31.665751","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.20.644150","title":"A CRITICAL ROLE FOR NEUTRAL SPHINGOMYELINASE-2 IN DOXORUBICIN-INDUCED CARDIOTOXICITY","date":"2025-03-20","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.20.644150","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.09.06.674659","title":"Unconventional secretion of angiogenic sonic-hedgehog-containing large extracellular vesicles is stimulated via the PI3K–Rab18-GDP pathway","date":"2025-09-06","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.06.674659","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.08.18.670814","title":"Risperidone regulates the expression of schizophrenia-related genes in the murine forebrain","date":"2025-08-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.18.670814","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.11.659159","title":"Sulindac modulates the response of triple negative breast cancer to anti-PD-L1 immunotherapy","date":"2025-06-17","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.11.659159","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":37365,"output_tokens":8790,"usd":0.121972,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18805,"output_tokens":5007,"usd":0.1096,"stage2_stop_reason":"end_turn"},"total_usd":0.231572,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structure of the human nSMase2 catalytic domain resolved at 1.85-Å reveals a DNase-I-type fold with a hydrophobic track leading to the active site blocked by an evolutionarily conserved 'DK switch' motif. The soluble catalytic domain directly interacts with the membrane-associated N-terminal domain (NTD), which serves as both a membrane anchor and an allosteric activator. The juxtamembrane region linking NTD and catalytic domain is necessary and sufficient for activation. Mutation of the conserved Asp residue in the DK switch disrupts catalysis, allosteric activation, stimulation by phosphatidylserine, and inhibition by GW4869.\",\n      \"method\": \"Crystal structure (1.85 Å), active-site mutagenesis, in vitro enzyme activity assays, reconstitution of allosteric activation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with mutagenesis and in vitro enzyme reconstitution in a single rigorous study\",\n      \"pmids\": [\"28652336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"SMPD3 is the primary neutral sphingomyelinase active in postnatal development; smpd3−/− mice are devoid of neutral sphingomyelinase activity and develop dwarfism and delayed puberty caused by hypothalamus-induced combined pituitary hormone deficiency. SMPD3 is segregated into detergent-resistant subdomains of Golgi membranes of hypothalamic neurosecretory neurons, where its transient activation modifies the lipid bilayer as an essential step in the Golgi secretory pathway.\",\n      \"method\": \"Knockout mouse generation (smpd3−/− and smpd2−/−smpd3−/− double mutant), biochemical SMase activity assay, subcellular fractionation into detergent-resistant membrane domains\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with defined enzymatic and phenotypic readout, replicated in double-mutant model\",\n      \"pmids\": [\"15764706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A deletion in the Smpd3 gene (fragilitas ossium mutation) results in complete loss of SMPD3 enzymatic activity and causes a syndrome of osteogenesis and dentinogenesis imperfecta in mice without detectable collagen defect, establishing SMPD3's enzymatic activity as essential for bone and dentin mineralization.\",\n      \"method\": \"Positional cloning, enzymatic activity assay confirming loss of activity in fro/fro mice\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — positional cloning with enzymatic loss-of-function confirmation and defined skeletal phenotype\",\n      \"pmids\": [\"16025116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SMPD3 deficiency disrupts homeostasis of the sphingomyelin–ceramide–diacylglycerol cycle in the Golgi SMPD3-SMS1 compartment. Loss of the fusogenic lipid intermediates ceramide and DAG impairs vesicle formation and transport in the Golgi secretory pathway, causing dysproteostasis, unfolded protein response, ER stress, and apoptosis. In chondrocytes this arrests secretion of extracellular matrix proteins causing skeletal malformation; in hypothalamic neurons it retards proteo-hormone secretion.\",\n      \"method\": \"smpd3−/− mouse and derived primary chondrocytes; lipidomics (SM, Cer, DAG quantification); immunofluorescence; assessment of UPR/ER stress markers\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — unbiased genetic model with multiple orthogonal biochemical and cell-biological readouts\",\n      \"pmids\": [\"27882938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TNF-α stimulates acute translocation of nSMase2 from a basal location to the plasma membrane of A549 epithelial cells in a time- and dose-dependent manner, and rapidly increases N-SMase activity. This translocation is regulated by p38-alpha MAPK (but not ERK or JNK); p38 MAPK inhibition abrogates the TNF-α-induced increase in endogenous N-SMase activity. Both p38-alpha MAPK and nSMase2 are required for TNF-α-stimulated up-regulation of VCAM-1 and ICAM-1, largely independently of NF-κB.\",\n      \"method\": \"Fluorescence microscopy (translocation), in vitro N-SMase activity assay, pharmacological p38/ERK/JNK inhibitors, nSMase2 overexpression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (localization + activity assay + downstream adhesion molecule readout) in single lab\",\n      \"pmids\": [\"17085432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PKC-delta mediates TNF-α- and PMA-stimulated translocation of nSMase2 from the Golgi to the plasma membrane. PKC-delta acts independently of p38 MAPK for translocation, but does not regulate in vitro N-SMase activity, and PKC-delta and nSMase2 do not co-immunoprecipitate, suggesting indirect regulation. PKC-delta is upstream of nSMase2-dependent induction of VCAM-1 and ICAM-1.\",\n      \"method\": \"Pharmacological PKC inhibitors, siRNA knockdown of PKC isoforms, fluorescence microscopy of nSMase2 translocation, in vitro N-SMase activity assay, co-immunoprecipitation (negative for direct interaction)\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods but single lab; co-IP was negative, indirect regulation inferred\",\n      \"pmids\": [\"18653803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"nSMase2 is a phosphoprotein phosphorylated exclusively at serine residues. Calcineurin (PP2B) binds directly to nSMase2 and acts as an on/off switch for its phosphorylation: under oxidative stress, calcineurin is inhibited/degraded, releasing nSMase2 from dephosphorylation, resulting in elevated phosphorylation and increased enzymatic activity. A mutant lacking the calcineurin-binding site shows constitutively elevated phosphorylation and activity that no longer responds to oxidative stress.\",\n      \"method\": \"Phospho-protein analysis (serine-specific), co-immunoprecipitation of calcineurin with nSMase2, calcineurin inhibitors/siRNA, active-site binding-site mutant, in vitro N-SMase activity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct co-IP of calcineurin with nSMase2 plus binding-site mutagenesis and functional activity readout in single rigorous study\",\n      \"pmids\": [\"20106976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Heterologous expression of mouse NSMase2 in primary rat hepatocytes generates a Mg2+-dependent, EDTA-inhibited and Triton-inhibited neutral sphingomyelinase that increases cellular ceramide levels, demonstrating in situ enzymatic activity. FLAG-tagged NSMase2 localizes to the plasma membrane by immunofluorescence. NSMase2 expression potentiates IL-1β-induced JNK phosphorylation via a PP2A-family phosphatase, possibly by modulating phosphorylation of IRAK.\",\n      \"method\": \"Adenovirus-mediated gene transfer, in vitro SMase activity assay, ceramide measurement, immunofluorescence localization, JNK phosphorylation assay, PP2A family phosphatase involvement\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple methods (enzymatic activity, localization, signaling readout) but single lab\",\n      \"pmids\": [\"15059969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"nSMase2 is the primary TNF-α-responsive N-SMase isoform in MCF-7 cells; TNF-α induces late increases in N-SMase activity through post-transcriptional mechanisms. Overexpression of nSMase2 (but not nSMase1 or nSMase3) significantly increases cellular ceramide and decreases sphingomyelin. siRNA knockdown of nSMase2 (but not nSMase3) inhibits TNF-α-induced N-SMase activity.\",\n      \"method\": \"siRNA knockdown, overexpression, in vitro N-SMase activity assay, cellular sphingolipid measurement by mass spectrometry\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (KD + OE + lipid measurement) in single lab\",\n      \"pmids\": [\"21303347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"nSMase2 (nSMase2/SMPD3) regulates exosomal microRNA secretion from cancer cells; its activity is required for exosome-mediated transfer of miR-210 to endothelial cells, which suppresses specific target genes to enhance angiogenesis and promote metastasis.\",\n      \"method\": \"nSMase2 knockdown/overexpression in cancer cells, exosome isolation, miRNA profiling, functional angiogenesis and metastasis assays in tumor models\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic manipulation with defined mechanistic readout (exosome miRNA content + angiogenesis) but single lab\",\n      \"pmids\": [\"23439645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Reconstitution of SMPD3 expression in mouse tumor cells lacking the endogenous gene enhances TNF-induced reduction of cell viability, and mutations found in human leukemia AML/ALL cases cause defects in SMPD3 protein stability and localization, demonstrating that SMPD3 function (ceramide pathway) contributes to apoptotic responses in hematopoietic tumor cells.\",\n      \"method\": \"SMPD3 reconstitution in tumor cell lines, cell viability assay with TNF treatment, sequencing of mutants with functional analysis of stability and localization\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reconstitution experiment plus functional localization analysis of disease mutations, single lab\",\n      \"pmids\": [\"18299447\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In rat hippocampal ischemia, nSMase2 (but not aSMase) activity is induced early in astrocytes (not neurons), driving ceramide accumulation and production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Enhanced binding of nSMase2 with RACK1 and EED is observed post-ischemia. nSMase2 activation is mediated by p38 MAPK downstream of A2B adenosine receptor, and is not blocked via the RACK1/EED/TNF-α receptor pathway.\",\n      \"method\": \"Four-vessel occlusion and OGD ischemia models, immunoprecipitation (nSMase2 with RACK1/EED), SMase activity assay, p38 MAPK inhibition, A2BAR pharmacology, cytokine mRNA quantification\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus enzymatic assay plus pharmacological epistasis in a defined in vivo model, single lab\",\n      \"pmids\": [\"24007266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Smpd3 expression in both chondrocytes and osteoblasts is required for normal endochondral bone development. Transgenic rescue of Smpd3 in chondrocytes of fro/fro mice corrects cartilage but not bone abnormalities; conditional knockout in Osx-expressing cells (chondrocytes + osteoblasts) recapitulates the full fro/fro skeletal phenotype. PTHrP downregulates Smpd3 expression in chondrogenic cells through transcription factor SOX9.\",\n      \"method\": \"Cre-loxP conditional knockout (Col2a1-Cre and Osx-Cre), transgenic rescue, quantitative histology and bone analysis, gene expression analysis in ATDC5 cells\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple conditional genetic models with defined tissue-specific phenotypic rescue/recapitulation\",\n      \"pmids\": [\"27325675\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BMP2 stimulation upregulates smpd3 mRNA expression in C2C12 cells and the transcription factor Runx2 directly binds to Runx2-responsive elements (RRE) in the smpd3 promoter (at -562 to -557 and -355 to -350 regions) to activate its transcription.\",\n      \"method\": \"BMP2 treatment and Runx2 transfection in C2C12 cells, promoter-reporter assay, EMSA (electrophoretic mobility shift assay)\",\n      \"journal\": \"BMB reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA demonstrating direct Runx2 binding plus promoter-reporter, single lab\",\n      \"pmids\": [\"19250608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ATRA regulates nSMase2 transcriptionally through retinoic acid receptor-α via modulation of histone acetylation, independent of Sp1/Sp3/Runx2 and without increased promoter activity. HDAC inhibition with TSA induces nSMase2 comparably to ATRA. The histone acetyltransferases CBP and p300 are required for ATRA-induced nSMase2 expression. HDAC4 and/or HDAC5 act as negative transcriptional regulators of nSMase2.\",\n      \"method\": \"HDAC inhibitors, siRNA knockdown of CBP/p300/HDACs, reporter assays, RT-qPCR, chromatin analysis\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic and pharmacological perturbations of epigenetic regulators with defined transcriptional readout, single lab\",\n      \"pmids\": [\"27013100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SMPD3 deficiency in neuronal Golgi compartment impairs vesicular protein transport, causing accumulation of APP, Aβ, and phosphorylated Tau, dysproteostasis, UPR, and apoptosis in smpd3−/− mouse neurons, resulting in progressive cognitive decline with AD-like signatures.\",\n      \"method\": \"smpd3−/− mouse model, immunoblotting for APP/Aβ/pTau, UPR markers, cognitive/behavioral testing, Golgi transport assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic model with multiple defined molecular readouts, single lab\",\n      \"pmids\": [\"29725009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ER stress inhibits NSMase2 activity and elevates plasma membrane and intracellular cholesterol in endothelial cells. NSMase2 knockdown decreases eNOS phosphorylation and NO production by ~50% and ~40% respectively, while increasing PM cholesterol. NSMase2 overexpression in ER-stressed cells restores cholesterol to near-control levels and recovers NO production to ~68–74% of controls, establishing NSMase2 as a pivotal regulator of cholesterol homeostasis and eNOS activation.\",\n      \"method\": \"NSMase2 overexpression and knockdown in BAEC, cholesterol measurement (epifluorescence and cholesterol oxidase), eNOS phosphorylation assay, NO production measurement\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal OE/KD with multiple functional readouts, single lab\",\n      \"pmids\": [\"22063270\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZIKV infection induces both activity and gene expression of nSMase2/SMPD3 in cortical neurons. Silencing of SMPD3 reduces viral burden and exosome-mediated transmission of ZIKV. GW4869 (nSMase2 inhibitor) reduces ZIKV loads in neurons and in exosomes derived from these cells.\",\n      \"method\": \"SMPD3 siRNA knockdown, pharmacological inhibition (GW4869), exosome isolation, viral load quantification (qPCR), cryo-EM of neuronal exosomes\",\n      \"journal\": \"Emerging microbes & infections\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological knockdown with defined viral transmission readout, single lab\",\n      \"pmids\": [\"30866785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Cambinol inhibits nSMase2 enzyme activity in dose-responsive fashion and suppresses extracellular vesicle production, thereby reducing tau seed propagation in vitro. In vivo oral administration of cambinol reduces nSMase2 activity in the brain. Molecular docking analysis suggests cambinol targets the DK-switch in the nSMase2 active site.\",\n      \"method\": \"In vitro nSMase2 enzyme activity assay, EV production assay, tau propagation assay, oral in vivo dosing with brain activity measurement, molecular docking\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro enzymatic assay plus in vivo brain activity plus docking; molecular docking is computational, but enzymatic and EV data are experimental, single lab\",\n      \"pmids\": [\"29604274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"nSMase2 inhibition with GW4869 decreases transfer of oligomeric α-synuclein between neuron-like cells and reduces accumulation and aggregation of high-molecular-weight α-syn, establishing nSMase2-dependent EV biogenesis as a route for α-syn propagation.\",\n      \"method\": \"GW4869 pharmacological inhibition, α-syn transfer assay between neuron-like cells, western blot for α-syn aggregates\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological inhibition with defined protein transfer readout; no genetic confirmation, single lab\",\n      \"pmids\": [\"31555088\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"nSMase2 deficiency or GW4869 pharmacological inhibition reduces atherosclerotic lesion development in Apoe−/− mice. The anti-inflammatory mechanism involves Nrf2 activation in endothelial cells and macrophages: GW4869 fails to protect when Nrf2 is silenced by siRNA in endothelial cells and is ineffective in LPS-stimulated macrophages from Nrf2-KO mice.\",\n      \"method\": \"Apoe−/−;Smpd3 genetic mouse model, GW4869 pharmacological inhibition, Nrf2 siRNA knockdown in endothelial cells, macrophages from Nrf2-KO mice, inflammatory gene expression (MCP-1, ICAM-1, VCAM-1 mRNA)\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic + pharmacological inhibition with epistasis through Nrf2 KO/KD, single lab\",\n      \"pmids\": [\"29794115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Postnatal ablation of Smpd3 causes impaired extracellular matrix mineralization and defective chondrocyte apoptosis at fracture sites. BMP-2 positively regulates Smpd3 expression via p38 MAPK in ATDC5 chondrogenic cells, while PTHrP negatively regulates Smpd3 expression, establishing opposing upstream regulators of SMPD3 in chondrocytes.\",\n      \"method\": \"Inducible conditional Smpd3 knockout (Smpd3flox/flox; Osx-Cre), tibial fracture model, p38 MAPK inhibition, gene expression analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible genetic model with fracture healing phenotype plus pharmacological pathway dissection, single lab\",\n      \"pmids\": [\"30530524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Human tau expression in PS19 transgenic mice elevates brain ceramide levels and nSMase2 activity. The selective nSMase2 inhibitor PDDC normalizes both, reduces tau immunostaining, hippocampal neuronal layer thinning, glial activation, and lowers pTau-carrying neuronal-derived EVs in plasma. In a direct tau propagation model, PDDC blocks contralateral spread of tau, confirming nSMase2-generated ceramide drives EV-mediated tau propagation.\",\n      \"method\": \"Transgenic PS19 mouse model, nSMase2 activity assay, ceramide/sphingomyelin measurement, AAV tau-propagation model, immunohistochemistry, plasma EV isolation and pTau quantification, PDDC oral treatment\",\n      \"journal\": \"Translational neurodegeneration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo pharmacological inhibition with multiple orthogonal readouts in two mouse models, single lab\",\n      \"pmids\": [\"38049923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In murine TLR signaling models of SLE, TLR activation induces abnormal expression of SMPD3 and triggers its translocation from the Golgi apparatus. SMPD3 dysfunction in turn enhances TLR-induced inflammatory responses in B cells and macrophages.\",\n      \"method\": \"Immunofluorescence of SMPD3 Golgi localization and redistribution, gene expression analysis, B cell and macrophage functional assays with TLR stimulation\",\n      \"journal\": \"Scandinavian journal of immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, immunofluorescence localization with limited mechanistic follow-up\",\n      \"pmids\": [\"28889482\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"DPTIP, a non-competitive inhibitor of nSMase2, blocks the DK-switch mechanism. Mutation of His463 in nSMase2 reduces DPTIP inhibitory activity, identifying His463 as a crucial residue in the allosteric inhibitory cavity. DPTIP shows antiviral activity against WNV (EC50 0.26 µM) and ZIKV (EC50 1.56 µM) through nSMase2 inhibition.\",\n      \"method\": \"In vitro nSMase2 activity assay with DPTIP, site-directed mutagenesis of H463A, computational docking, antiviral assay in cell culture\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with enzymatic assay and computational validation in single study, single lab\",\n      \"pmids\": [\"36430407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SMPD3 expression in odontoblasts is regulated by the Shh-Gli1 pathway: Smpd3 knockdown impairs odontoblast differentiation and reduces Dspp/Dmp1 markers, while Smpd3 overexpression enhances dentinogenic differentiation and promotes dentin formation ex vivo in a Shh-dependent manner.\",\n      \"method\": \"siRNA knockdown and overexpression in mDPCs, bulk RNA sequencing, Shh pathway inhibition, tooth germ culture, mineralization assays\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic manipulation (KD + OE) with pathway validation (Shh inhibition) and ex vivo confirmation, single lab\",\n      \"pmids\": [\"40639673\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SOXE-family transcription factors SOX9 and SOX10 directly regulate SMPD3 expression in migrating neural crest cells via enhancer sequences in the first intron of the SMPD3 locus. ChIP-seq and nascent transcription analysis confirm that SOX10 directly drives expression of an SMPD3 enhancer specific to migratory neural crest cells.\",\n      \"method\": \"Enhancer-reporter assay, transcription factor knockdown, ChIP-seq, nascent transcription analysis (GRO-seq or equivalent), in vivo chick/Xenopus neural crest models\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq plus functional enhancer-reporter plus TF knockdown in a defined developmental context, single lab\",\n      \"pmids\": [\"38052296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NSMase2 (fro/fro) deficiency leads to accumulation of sphingomyelin and dramatic reduction of ceramides in fibroblasts, and causes slow growth with G1/G0 arrest that is corrected by smpd3 transfection, indicating NSMase2 generates ceramides required for cell cycle progression. ASMase mRNA, protein and activity are substantially elevated in fro/fro fibroblasts, suggesting compensatory upregulation; ASMase deficiency does not affect NSMase2 activity.\",\n      \"method\": \"fro/fro and ASMase−/− mutant mouse fibroblasts, sphingolipid measurement, SMase activity assay, cell cycle analysis, smpd3 transfection rescue\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic rescue experiment with cell cycle and lipid readouts, single lab\",\n      \"pmids\": [\"23046545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Proximity labeling (APEX2) of nSMase2 in Jurkat cells reveals a plasma membrane proximal protein network that undergoes significant dynamic remodeling within the first 5 minutes of TNFα stimulation. The recruitment of most proximal proteins depends on nSMase2 enzymatic activity. Proteins related to vesicle-mediated transport (recycling endosomes, trans-Golgi network, exocytic vesicles) are significantly enriched in the proximitome of enzymatically active nSMase2 upon TNFα stimulation.\",\n      \"method\": \"APEX2 proximity labeling, streptavidin affinity purification, quantitative mass spectrometry, nSMase2-APEX2 stable cell line\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity proteomics with enzymatic activity dependence confirmed, single lab\",\n      \"pmids\": [\"39044828\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Glucocorticoids stimulate sEV secretion in neuronal cells through nSMase2 and Rab27a. GC-induced sEV release requires mitochondrial reactive oxygen species production and opening of the mitochondrial permeability transition pore (mPTP) upstream of nSMase2 activation, linking mitochondrial damage to ceramide-driven EV biogenesis.\",\n      \"method\": \"TIRF microscopy with mCh-CD63-pHluorin pH-sensitive sEV marker, Rab27a and nSMase2 knockdown, mPTP inhibitors, ROS measurement\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live imaging of EV release combined with genetic knockdown and pharmacological pathway dissection, single lab\",\n      \"pmids\": [\"42059363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HIF-1α is identified as a direct transcriptional activator of SMPD3 in hepatocytes during alcohol-associated liver disease: ChIP assay demonstrates HIF-1α binding to the SMPD3 locus, and liver-specific Hif1α knockdown reduces hepatic SMPD3 expression. Silencing SMPD3 alleviates alcohol-induced lipid accumulation in hepatocytes.\",\n      \"method\": \"ChIP assay (HIF-1α at SMPD3 locus), liver-specific Hif1α knockdown mouse, SMPD3 siRNA in hepatocytes, ceramide measurement\",\n      \"journal\": \"Journal of agricultural and food chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct transcriptional regulation plus genetic KD with functional lipid readout, single lab\",\n      \"pmids\": [\"40404566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CRISPR/Cas9-generated heterozygous full-body and conditional Smpd3 knockout mice show no impact of Smpd3 deficiency on EV release in vitro or in vivo, challenging the view that nSMase2 universally drives EV biogenesis and suggesting a cell-type-specific role. Bone marrow-derived macrophages show reduced EV release only upon Alix deletion, not Smpd3 deletion.\",\n      \"method\": \"CRISPR/Cas9 Smpd3 knockout mice (full-body and conditional), in vitro and in vivo EV quantification, Alix deletion comparison\",\n      \"journal\": \"Journal of extracellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with rigorous in vitro and in vivo EV measurement; negative result for nSMase2's universal EV role, single lab\",\n      \"pmids\": [\"39525277\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SMPD3/nSMase2 is a Mg2+-dependent neutral sphingomyelinase localized to the Golgi membrane and plasma membrane that hydrolyzes sphingomyelin to ceramide and phosphocholine; its catalytic domain adopts a DNase-I fold regulated by an allosteric 'DK switch' activated by an interdomain interaction with the membrane-anchored N-terminal domain and by phosphatidylserine; ceramide and DAG produced by SMPD3 in the Golgi are required for vesicle budding and secretory pathway flux in chondrocytes and hypothalamic neurons, and at the plasma membrane ceramide enrichment drives ESCRT-independent exosome/EV biogenesis that mediates intercellular transfer of miRNAs, tau, and α-synuclein; nSMase2 is activated by TNF-α downstream of p38 MAPK and PKC-delta (controlling its Golgi-to-plasma membrane translocation) and is negatively regulated by calcineurin-mediated dephosphorylation; upstream transcriptional regulators include Runx2, SOX9/SOX10, CBP/p300-mediated histone acetylation (via ATRA/RAR-α), and HIF-1α.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SMPD3 (nSMase2) is a Mg2+-dependent, membrane-associated neutral sphingomyelinase that hydrolyzes sphingomyelin to ceramide, and is the principal neutral sphingomyelinase active in postnatal development [#1, #7]. Its catalytic domain adopts a DNase-I-type fold whose active site is gated by a conserved 'DK switch'; catalysis requires an allosteric interaction with the membrane-anchored N-terminal domain via a juxtamembrane region, and a conserved Asp in the DK switch is essential for activity, allosteric activation, phosphatidylserine stimulation, and GW4869 inhibition [#0]. The ceramide and diacylglycerol generated by SMPD3 in the Golgi SMPD3–SMS1 compartment serve as fusogenic intermediates required for secretory vesicle formation; loss of these lipids in smpd3-deficient cells impairs Golgi vesicle transport and drives dysproteostasis, ER stress, and apoptosis, arresting extracellular matrix secretion in chondrocytes and proteo-hormone secretion in hypothalamic neurons [#1, #3]. This secretory function makes SMPD3 enzymatic activity essential for endochondral bone and dentin mineralization, where its loss causes osteogenesis/dentinogenesis imperfecta-like skeletal disease in mice [#2, #12]. At the plasma membrane, ceramide enrichment by SMPD3 supports extracellular vesicle/exosome biogenesis that mediates intercellular transfer of cargo including miRNAs, tau, and \\u03b1-synuclein [#9, #19, #22], although a genetic knockout study found EV release to be cell-type-specific rather than universally SMPD3-dependent [#31]. SMPD3 is acutely activated downstream of TNF-\\u03b1 through p38 MAPK and PKC-delta, which control its Golgi-to-plasma-membrane translocation, and is held in check by direct binding of calcineurin, which dephosphorylates and inactivates it [#4, #5, #6]. Transcriptionally, SMPD3 is driven by Runx2, SOX9/SOX10, retinoic-acid-receptor-mediated histone acetylation via CBP/p300, and HIF-1\\u03b1 in tissue-specific contexts [#13, #26, #14, #30].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Establishing that nSMase2 is a genuine cellular enzyme answered whether the cloned protein generates ceramide in situ and where it acts.\",\n      \"evidence\": \"Heterologous adenoviral expression in rat hepatocytes with in vitro SMase assay, ceramide measurement, and immunofluorescence\",\n      \"pmids\": [\"15059969\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Localization to plasma membrane only in overexpression context\", \"Mg2+ dependence shown biochemically but native regulation unaddressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Knockout and positional-cloning studies established SMPD3 as the dominant postnatal neutral sphingomyelinase and tied its enzymatic loss to defined developmental phenotypes.\",\n      \"evidence\": \"smpd3\\u2212/\\u2212 mice and fro/fro mutant with SMase activity assays, subcellular fractionation, and skeletal/endocrine phenotyping\",\n      \"pmids\": [\"15764706\", \"16025116\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between Golgi ceramide and secretory defect not yet mechanistic\", \"Bone mineralization mechanism unresolved at this stage\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identifying TNF-\\u03b1-driven p38 MAPK control of nSMase2 translocation answered how the enzyme is acutely mobilized in inflammatory signaling.\",\n      \"evidence\": \"Fluorescence microscopy of translocation, in vitro N-SMase activity, and pharmacological p38/ERK/JNK inhibition in A549 cells\",\n      \"pmids\": [\"17085432\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct effector linking p38 to nSMase2 not identified\", \"Translocation target compartment defined only as plasma membrane\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"PKC-delta was placed as a second, p38-independent regulator of nSMase2 translocation, refining the signaling architecture of activation.\",\n      \"evidence\": \"PKC inhibitors, siRNA of PKC isoforms, translocation microscopy, activity assay, and negative co-IP\",\n      \"pmids\": [\"18653803\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Regulation inferred to be indirect; no direct PKC-delta–nSMase2 interaction\", \"Intermediate effector between PKC-delta and translocation unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery that calcineurin directly binds and dephosphorylates nSMase2 established a phosphorylation on/off switch coupling oxidative stress to enzyme activity.\",\n      \"evidence\": \"Serine-phospho analysis, calcineurin co-IP, calcineurin-binding-site mutant, and activity assays\",\n      \"pmids\": [\"20106976\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for the activating phosphorylation not identified\", \"Specific phosphoserine sites not mapped\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Isoform-specificity and cholesterol/eNOS work showed nSMase2 is the chief TNF-responsive N-SMase and a regulator of membrane lipid homeostasis beyond ceramide.\",\n      \"evidence\": \"siRNA/overexpression of nSMase isoforms with mass-spec lipid measurement; reciprocal OE/KD in endothelial cells with cholesterol and NO readouts\",\n      \"pmids\": [\"21303347\", \"22063270\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking ceramide to cholesterol redistribution unresolved\", \"Post-transcriptional TNF-\\u03b1 induction mechanism undefined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linking nSMase2 to exosomal miRNA secretion and to ischemic astrocyte inflammation extended its role from intracellular trafficking to intercellular signaling.\",\n      \"evidence\": \"nSMase2 knockdown/overexpression with exosome isolation and miRNA transfer assays; ischemia models with nSMase2–RACK1/EED co-IP and p38/A2BAR pharmacology\",\n      \"pmids\": [\"23439645\", \"24007266\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RACK1/EED interaction functional consequence not resolved\", \"Whether ceramide directly nucleates exosomal cargo loading untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defining the SMPD3-SMS1 sphingomyelin–ceramide–DAG cycle and tissue-specific genetic dissection established the mechanism by which SMPD3 loss disrupts the secretory pathway and bone development.\",\n      \"evidence\": \"smpd3\\u2212/\\u2212 mice and chondrocytes with lipidomics and UPR markers; conditional Cre-loxP knockouts and transgenic rescue; ATRA/CBP/p300 transcriptional analysis\",\n      \"pmids\": [\"27882938\", \"27325675\", \"27013100\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of vesicle-budding machinery sensing ceramide/DAG unknown\", \"How epigenetic regulation integrates with developmental signals unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"The crystal structure resolved the catalytic mechanism, revealing the DNase-I fold, the DK-switch gate, and allosteric activation by the membrane-anchored NTD.\",\n      \"evidence\": \"1.85-\\u00c5 crystal structure with active-site mutagenesis and reconstitution of allosteric activation\",\n      \"pmids\": [\"28652336\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length membrane-embedded structure not solved\", \"Conformational dynamics of DK-switch in vivo not captured\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Connecting SMPD3 to tumor apoptotic responses, AML/ALL mutations, and skeletal/dental developmental signaling broadened its disease relevance and identified druggable inhibition of the DK switch.\",\n      \"evidence\": \"SMPD3 reconstitution and TNF viability assays with disease-mutant stability/localization analysis; cambinol enzyme/EV/tau assays with docking; inducible chondrocyte knockout fracture model\",\n      \"pmids\": [\"18299447\", \"29604274\", \"30530524\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether AML/ALL mutations are driver events untested\", \"In vivo selectivity of cambinol for the DK switch not confirmed structurally\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Pharmacological and genetic inhibition established nSMase2-dependent EV biogenesis as a conserved route for spread of pathogenic proteins and viruses and for vascular inflammation.\",\n      \"evidence\": \"GW4869 and siRNA studies of \\u03b1-syn and ZIKV transfer; Apoe\\u2212/\\u2212;Smpd3 atherosclerosis model with Nrf2 epistasis; AD-like phenotype in smpd3\\u2212/\\u2212 neurons\",\n      \"pmids\": [\"31555088\", \"30866785\", \"29794115\", \"29725009\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"\\u03b1-syn work lacks genetic confirmation\", \"Mechanism linking ceramide EVs to Nrf2 activation undefined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"In vivo inhibitor work and additional structural/transcriptional studies confirmed ceramide-driven EV-mediated tau propagation and mapped further regulatory inputs to SMPD3.\",\n      \"evidence\": \"PS19 tauopathy and tau-propagation models with selective nSMase2 inhibitor PDDC; DPTIP/H463A DK-switch mutagenesis with antiviral assays; SOX9/SOX10 ChIP-seq and enhancer analysis; Shh-Gli1 odontoblast study\",\n      \"pmids\": [\"38049923\", \"36430407\", \"38052296\", \"40639673\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether plasma EV pTau is a faithful biomarker of brain activity not established\", \"His463 allosteric cavity not structurally resolved with bound inhibitor\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Proximity proteomics and a rigorous knockout challenged the universality of nSMase2-driven EV release, defining its trafficking proximitome while revealing cell-type-specific dependence.\",\n      \"evidence\": \"APEX2 proximity labeling in Jurkat cells with TNF\\u03b1 stimulation; CRISPR/Cas9 Smpd3 knockout mice with in vitro/in vivo EV quantification and Alix comparison\",\n      \"pmids\": [\"39044828\", \"39525277\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding partners within the proximitome not validated\", \"Determinants of cell-type EV dependence unidentified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Stress-coupled regulation studies linked mitochondrial damage and HIF-1\\u03b1 transcription to SMPD3 activation in neuronal EV release and hepatic lipid handling.\",\n      \"evidence\": \"TIRF imaging of glucocorticoid-induced sEV release with nSMase2/Rab27a knockdown and mPTP/ROS dissection; HIF-1\\u03b1 ChIP and liver-specific knockdown with ceramide readout\",\n      \"pmids\": [\"42059363\", \"40404566\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism coupling mitochondrial ROS/mPTP to nSMase2 activation undefined\", \"Direct vs indirect HIF-1\\u03b1 binding site not mapped at base resolution\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved which cell types and physiological contexts genuinely require SMPD3 for EV biogenesis versus secretory trafficking, and what kinase and effector machinery couple upstream signals to its activation and vesicle budding.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type determinants of EV dependence unknown\", \"Activating kinase and ceramide-sensing budding machinery unidentified\", \"Full-length membrane-embedded structure and in-cell DK-switch dynamics unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1, 7]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 7, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [1, 3, 5, 23]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4, 5, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [3, 8, 27]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [9, 22]},\n      {\"term_id\": \"R-HSA-9609507\", \"supporting_discovery_ids\": [1, 3, 15]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [9, 28, 29]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [12, 26]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"SMS1\", \"CALCINEURIN\", \"RACK1\", \"EED\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}